In mice with established subcutaneous B16.F0 tumors, peritumoral injection of CXCL13 and CCL21, combined with intraperitoneal anti–PD-L1 therapy, increased intratumoral TLS formation and significantly enhanced tumor suppression [51]. This evidence concerns the gene CCL21 and neoplasm.